Products
Trevotamig Biosimilar Bispecific Antibody (EpCAM × CD3) for Research
Cat No.: GMP-Bios-INN-1427
Anti-EPCAM/CD326 therapeutic antibody (Pre-made Trevotamig biosimilar,Bispecific Mixed Domains (H-gamma1_L-kappa-scFvhl)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Trevotamig is a humanized bispecific antibody targeting EPCAM, CD326 and CD3. It is developed by Wuhan YZY Biopharma Co., Ltd. for Malignant Pleural Effusions, NSCLC Stage IV in Phase I/II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1427-1mg | 1mg | |
| GMP-Bios-INN-1427-10mg | 10mg | |
| GMP-Bios-INN-1427-100mg | 100mg | |
| GMP-Bios-INN-1427-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Trevotamig biosimilar, Bispecific Mixed Domains (H-gamma1_L-kappa-scFvhl), Anti-EPCAM/CD326;CD3E Antibody: Anti-EPCAM/CD326/Epithelial cell adhesion molecule/Ep-CAM therapeutic antibody |
| INN Name | Trevotamig |
| Target | EPCAM/CD326;CD3E |
| Format | Bispecific Mixed Domains (H-gamma1_L-kappa-scFvhl) |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;na |
| VD LC | Kappa;Lambda |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
